Adenosine kinase regulation of cardiomyocyte hypertrophy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 5, 2011, Pages

  Fassett, John T ^a   Hu, Xinli ^a   Xu, Xin ^a   Lu, Zhongbing ^a   Zhang, Ping ^a   Chen, Yingjie ^a   Bache, Robert J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

2 chloroadenosine; P70s6 kinase; Raf

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLOROADENOSINE; 5 IODOTUBERCIDIN; 8 (4 SULFOPHENYL)THEOPHYLLINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ABT 702; ADENOSINE KINASE; ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR; ATRIAL NATRIURETIC FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHENYLEPHRINE; RAF PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CELL SIZE; CELL SURFACE; CONTROLLED STUDY; HEART HYPERTROPHY; HEART MUSCLE CELL; INTRACELLULAR SIGNALING; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; RNA INTERFERENCE; WESTERN BLOTTING;

ADENOSINE; ADENOSINE KINASE; ANIMALS; CELLS, CULTURED; ENZYME INHIBITORS; HYPERTROPHY; MODELS, ANIMAL; MORPHOLINES; MYOCYTES, CARDIAC; PROTEIN KINASES; PYRIMIDINES; RAF KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79955768817     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00684.2010     Document Type: Article

References (45)

1. Aoki H, Sadoshima J, Izumo S. Myosin light chain kinase mediates sarcomere organization during cardiac hypertrophy in vitro. Nat Med 6: 183-188, 2000.
2. Barron AJ, Finn SG, Fuller SJ. Chronic activation of extracellularsignal- regulated protein kinases by phenylephrine is required to elicit a hypertrophic response in cardiac myocytes. Biochem J 371: 71-79, 2003.
3. Black RG Jr. Guo Y, Ge ZD, Murphree SS, Prabhu SD, Jones WK, Bolli R, and, Auchampach JA. Gene dosage-dependent effects of cardiac- specific overexpression of the A3 adenosine receptor. Circ Res 91: 165-172, 2002.
4. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279: 32771-32779, 2004.
5. Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 103: 203-215, 2008.
6. da Silva CG, Jarzyna R, Specht A, Kaczmarek E. Extracellular nucleotides and adenosine independently activate AMP-activated protein kinase in endothelial cells: involvement of P2 receptors and adenosine transporters. Circ Res 98: e39-47, 2006.
7. de Jong JW, de Jonge R, Keijzer E, Bradamante S. The role of adenosine in preconditioning. Pharmacol Ther 87: 141-149, 2000.
8. de Jonge N, Goumans MJ, Lips D, Hassink R, Vlug EJ, van der Meel R, Emmerson CD, Nijman J, de Windt L, Doevendans PA. Controlling cardiomyocyte survival. Novartis Found Symp 274: 41-51, discussion 51-47, 152-155, 272-156, 2006.
9. Deussen A, Stappert M, Schafer S, Kelm M. Quantification of extracellular and intracellular adenosine production: understanding the transmembranous concentration gradient. Circulation 99: 2041-2047, 1999.
10. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation 96: 2656-2666, 1997.
11. Fassett JT, Xu X, Hu X, Zhu G, French J, Chen Y, Bache RJ. Adenosine regulation of microtubule dynamics in cardiac hypertrophy. Am J Physiol Heart Circ Physiol 297: H523-H532, 2009.
12. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 362: 364-374, 2000.
13. Funakoshi H, Chan TO, Good JC, Libonati JR, Piuhola J, Chen X, MacDonnell SM, Lee LL, Herrmann DE, Zhang J, Martini J, Palmer TM, Sanbe A, Robbins J, Houser SR, Koch WJ, Feldman AM. Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation 114: 2240-2250, 2006.
14. Gan XT, Rajapurohitam V, Haist JV, Chidiac P, Cook MA, Karmazyn M. Inhibition of phenylephrine-induced cardiomyocyte hypertrophy by activation of multiple adenosine receptor subtypes. J Pharmacol Exp Ther 312: 27-34, 2005.
15. Gao XM, Wong G, Wang B, Kiriazis H, Moore XL, Su YD, Dart A, Du XJ. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens 24: 1663-1670, 2006.
16. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226, 2008.
17. Haynes J Jr, Killilea DW, Peterson PD, and Thompson WJ. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3=,5=-guanosine monophosphate- stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung. J Pharmacol Exp Ther 276: 752-757, 1996.
18. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590, 2003.
19. Klesse LJ, Parada LF. p21 ras and phosphatidylinositol-3 kinase are required for survival of wild-type and NF1 mutant sensory neurons. J Neurosci 18: 10420-10428, 1998.
20. Koshiba M, Kosaka H, Nakazawa T, Hayashi N, Saura R, Kitamura N, Kumagai S. 2-Chloroadenosine but not adenosine induces apoptosis in rheumatoid fibroblasts independently of cell surface adenosine receptor signalling. Br J Pharmacol 135: 1477-1486, 2002.
21. Kroll K, Decking UK, Dreikorn K, Schrader J. Rapid turnover of the AMP-adenosine metabolic cycle in the guinea pig heart. Circ Res 73: 846-856, 1993.
22. L, Mounier R, Leclerc J, Pende M, Foretz M, Viollet B. Coordinated maintenance of muscle cell size control by AMP-activated protein kinase. FASEB J 24: 3555-3561.
23. Lasley RD, Smart EJ. Cardiac myocyte adenosine receptors and caveolae. Trends Cardiovasc Med 11: 259-263, 2001.
24. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 47: 443-467, 2007.
25. Lenormand P, McMahon M, Pouyssegur J. Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway. J Biol Chem 271: 15762-15768, 1996.
26. Liao Y, Takashima S, Asano Y, Asakura M, Ogai A, Shintani Y, Minamino T, Asanuma H, Sanada S, Kim J, Ogita H, Tomoike H, Hori M, Kitakaze M. Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 93: 759-766, 2003.
27. Lu Z, Fassett J, Xu X, Hu X, Zhu G, French J, Zhang P, Schnermann J, Bache RJ, Chen Y. Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle. Circulation 118: 1713-1721, 2008.
28. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109: 3050-3055, 2004.
29. Mery PF, Pavoine C, Pecker F, Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol 48: 121-130, 1995.
30. Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 52: 25-39, 2001.
31. Narayan P, Mentzer RM Jr, Lasley RD. Adenosine A1 receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes. J Mol Cell Cardiol 33: 121-129, 2001.
32. Pang T, Gan XT, Freeman DJ, Cook MA, Karmazyn M. Compensatory upregulation of the adenosine system following phenylephrine-induced hypertrophy in cultured rat ventricular myocytes. Am J Physiol Heart Circ Physiol 298: H545-H553, 2010.
33. Pearson G, Bumeister R, Henry DO, Cobb MH, White MA. Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation. J Biol Chem 275: 37303-37306, 2000.
34. Peart JN, Headrick JP. Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther 114: 208-221, 2007.
35. Podgorska M, Kocbuch K, Grden M, Szutowicz A, Pawelczyk T. Prevalence of unidirectional Na-dependent adenosine transport and altered potential for adenosine generation in diabetic cardiac myocytes. Basic Res Cardiol 101: 214-222, 2006.
36. Purcell NH, Wilkins BJ, York A, Saba-El-Leil M.K, Meloche S, Robbins J, Molkentin JD. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 104: 14074-14079, 2007.
37. Reichelt ME, Shanu A, Willems L, Witting PK, Ellis NA, Blackburn MR, Headrick JP. Endogenous adenosine selectively modulates oxidant stress via the A1 receptor in ischemic hearts. Antioxid Redox Signal 11: 2641-2650, 2009.
38. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31: 342-348, 2006.
39. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen- activated protein kinases. Cell Signal 15: 813-827, 2003.
40. Tinton S, Buc-Calderon P. Homocysteine enhances the inhibitory effect of extracellular adenosine on the synthesis of proteins in isolated rat hepatocytes. Biochem J 310: 893-896, 1995.
41. Tran NH, Frost JA. Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J Biol Chem 278: 11221-11226, 2003.
42. Wakeno M, Minamino T, Seguchi O, Okazaki H, Tsukamoto O, Okada K, Hirata A, Fujita M, Asanuma H, Kim J, Komamura K, Takashima S, Mochizuki N, Kitakaze M. Long-term stimulation of adenosine A2b receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation 114: 1923-1932, 2006.
43. Xu X, Fassett J, Hu X, Zhu G, Lu Z, Li Y, Schnermann J, Bache RJ, Chen Y. Ecto-5=-nucleotidase deficiency exacerbates pressure-overloadinduced left ventricular hypertrophy and dysfunction. Hypertension 51: 1557-1564, 2008.
44. Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC, Kreutz R, Wang Y, Maleeff B, Parsons AA, Ohlstein EH. Extracellular signalregulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 275: 37895-37901, 2000.
45. Zhang W, Anger T, Su J, Hao J, Xu X, Zhu M, Gach A, Cui L, Liao R, Mende U. Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy. J Biol Chem 281: 5811-5820, 2006.